Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles using in silico clinical trials
Abstract Ovarian cancer is commonly diagnosed in its late stages, and new treatment modalities are needed to improve patient outcomes and survival. We have recently established the synergistic effects of combination tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and procaspase activ...
Main Authors: | Olivia Cardinal, Chloé Burlot, Yangxin Fu, Powel Crosley, Mary Hitt, Morgan Craig, Adrianne L. Jenner |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | Computational and Systems Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/cso2.1035 |
Similar Items
-
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro
by: Powel Crosley, et al.
Published: (2021-04-01) -
PACS for the Developing World
by: Jeffrey B. Mendel, et al.
Published: (2015-11-01) -
Análisis in silico de la expresión génica en células de granulosa de folículos preovulatorios en dos especies de bovinos
by: Jesús Alfredo Berdugo-Gutiérrez, et al.
Published: (2022-02-01) -
The effects of polycyclic aromatic compounds (PACs) on mammalian ovarian function
by: Genevieve A Perono, et al.
Published: (2022-01-01) -
The effect of ACVR1B/TGFBR1/ACVR1C signaling inhibition on oocyte and granulosa cell development during in vitro growth culture
by: Yuki AKIMOTO, et al.
Published: (2023-09-01)